DDInter458 DDInter1105
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression despite therapy with platinum-based agents. This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials.
Cyclosporine {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is bound by {v} (Compound) Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Cyclosporine {u} (Compound) causes {v} (Side Effect) Discomfort
Discomfort {u} (Side Effect) is caused by {v} (Compound) Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Cyclosporine {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Cyclosporine {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is bound by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Cyclosporine {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Cyclosporine {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Cyclosporine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Cyclosporine {u} (Compound) upregulates {v} (Gene) PMAIP1
PMAIP1 {u} (Gene) is upregulated by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Cyclosporine {u} (Compound) upregulates {v} (Gene) SESN1
SESN1 {u} (Gene) is downregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC1A4
SLC1A4 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Cyclosporine (Compound) downregulates DCK (Gene) and DCK (Gene) is bound by Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Cyclosporine (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Cyclosporine (Compound) downregulates DCK (Gene) and DCK (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Cyclosporine (Compound) downregulates DCK (Gene) and DCK (Gene) is bound by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Lurbinectedin
Cyclosporine (Compound) downregulates DCK (Gene) and DCK (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Lurbinectedin
Cyclosporine (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Lurbinectedin
Cyclosporine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Cyclosporine (Compound) upregulates PMAIP1 (Gene) and PMAIP1 (Gene) is upregulated by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Cyclosporine (Compound) upregulates SESN1 (Gene) and SESN1 (Gene) is downregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Cyclosporine (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Lurbinectedin